Loading...
Derniers dépôts
-
Florentin Pastor, Emilie Charles, Chiara Di Vona, Maëlys Chapelle, Michel Rivoire, et al.. The dual-specificity kinase DYRK1A interacts with the Hepatitis B virus genome and regulates the production of viral RNA. PLoS ONE, 2024, 19 (10), pp.e0311655. ⟨10.1371/journal.pone.0311655⟩. ⟨inserm-04843314⟩
-
Lena Allweiss, Barbara Testoni, Mei Yu, Julie Lucifora, Chunkyu Ko, et al.. Quantification of the Hepatitis B Virus cccDNA: Evidence-based guidelines for 2 monitoring the key obstacle of HBV cure 3 Short Title: cccDNA quantification harmonization 4 5. Gut, 2023, pp.gutjnl-2022-328380. ⟨10.1136/gutjnl-2022-328380⟩. ⟨hal-03992742⟩
-
Myriam Lamrayah, Fanny Charriaud, Manon Desmares, Céline Coiffier, Simon Megy, et al.. Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus. Antiviral Research, 2023, 209, pp.105483. ⟨10.1016/j.antiviral.2022.105483⟩. ⟨hal-03923266⟩
-
Manon Desmares, Marion Delphin, Brieux Chardès, Caroline Pons, Juliette Riedinger, et al.. Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes. Antiviral Research, 2022, 206, pp.105386. ⟨10.1016/j.antiviral.2022.105386⟩. ⟨hal-03869860⟩
-
Eloi R Verrier, Anna Salvetti, Caroline Pons, Maud Michelet, Michel Rivoire, et al.. Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method. Antiviral Research, 2022, 198, pp.105250. ⟨10.1016/j.antiviral.2022.105250⟩. ⟨hal-03540952⟩
Nombre de documents
18
Nombre de notices
Répartition par type de documents
Evolution